HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

sandramycin

depsipeptide, structure given in first source; isolated from Nocardioides sp. ATCC 39419

Also Known As:

Sandramycin

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - sandramycin: 3
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - sandramycin: 3

Experts

1.	Ichikawa, Satoshi: 1 article (03/2014)
2.	Katayama, Katsushi: 1 article (03/2014)
3.	Matsuda, Akira: 1 article (03/2014)
4.	Nakagawa, Koji: 1 article (03/2014)
5.	Okamura, Takuya: 1 article (03/2014)
6.	Shiro, Motoo: 1 article (03/2014)
7.	Sunadome, Takuya: 1 article (03/2014)
8.	Takeda, Hiroshi: 1 article (03/2014)

Related Diseases

1.	Melanoma (Melanoma, Malignant) 01/01/1998 - "Although typically 4-10x less potent than sandramycin against leukemia cell lines, it proved to be 1-10,000x more potent against melanomas, carcinomas, and adenocarcinomas exhibiting IC50 values of 1 pM-10 nM placing it among the most potent agents identified to date. "
2.	Leukemia 01/01/1998 - "Although typically 4-10x less potent than sandramycin against leukemia cell lines, it proved to be 1-10,000x more potent against melanomas, carcinomas, and adenocarcinomas exhibiting IC50 values of 1 pM-10 nM placing it among the most potent agents identified to date. "
3.	Carcinoma (Carcinomatosis) 01/01/1998 - "Although typically 4-10x less potent than sandramycin against leukemia cell lines, it proved to be 1-10,000x more potent against melanomas, carcinomas, and adenocarcinomas exhibiting IC50 values of 1 pM-10 nM placing it among the most potent agents identified to date. "
4.	Adenocarcinoma 01/01/1998 - "Although typically 4-10x less potent than sandramycin against leukemia cell lines, it proved to be 1-10,000x more potent against melanomas, carcinomas, and adenocarcinomas exhibiting IC50 values of 1 pM-10 nM placing it among the most potent agents identified to date. "
5.	Neoplasms (Cancer) 03/21/2014 - "It was suggested that 1 possesses biological behaviors similar to those of sandramycin (2) in terms of cytotoxic activity against human cancer cell lines (IC50 = 3.2-12 nM) and HIF-1 inhibitory activity."

Related Drugs and Biologics

1.	Depsipeptides